BioStock: Saniona’s CFO outlines clinical milestone strategy
According to Saniona’s Q1 2025 report, the company’s current financing is set to support the advancement of its three internal development programs – SAN711, SAN2219, and SAN2355 – toward significant clinical milestones. We reached out to CFO Johnny Stilou for a comment.
Read the full interview at biostock.se:
https://biostock.se/en/2025/06/sanionas-cfo-outlines-clinical-milestone-strategy/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/